Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors

[1]  J. Rees Neuro-oncology , 2010, Practical Neurology.

[2]  Andrew J. Lindsay,et al.  Rab-coupling protein coordinates recycling of α5β1 integrin and EGFR1 to promote cell migration in 3D microenvironments , 2008, The Journal of cell biology.

[3]  Kairbaan Hodivala-Dilke,et al.  alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment. , 2008, Current opinion in cell biology.

[4]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[5]  J. Norman,et al.  Endocytic transport of integrins during cell migration and invasion. , 2008, Trends in cell biology.

[6]  K. Hodivala-Dilke avb3 integrin and angiogenesis: a moody integrin in a changing environment , 2008 .

[7]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[8]  Daniel L. Gustafson,et al.  Assessment of the biological and pharmacological effects of the ανβ3 and ανβ5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors , 2007 .

[9]  J. Kirkwood,et al.  Integrins and cancer. , 2007, Oncology.

[10]  R. Stupp,et al.  Integrin inhibitors reaching the clinic. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  T. Mikkelsen,et al.  Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[13]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[14]  H. Friess,et al.  A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer , 2006, BMC Cancer.

[15]  J. Hickman,et al.  Blockade of αvβ3 and αvβ5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells , 2006 .

[16]  T. Byzova,et al.  Integrin signaling is critical for pathological angiogenesis , 2006, The Journal of experimental medicine.

[17]  J. Norman,et al.  VEGF regulates the mobilization of VEGFR2/KDR from an intracellular endothelial storage compartment. , 2006, Blood.

[18]  Gareth Howell,et al.  Intrinsic Tyrosine Kinase Activity is Required for Vascular Endothelial Growth Factor Receptor 2 Ubiquitination, Sorting and Degradation in Endothelial Cells , 2006, Traffic.

[19]  F. Orsenigo,et al.  Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments , 2006, The Journal of cell biology.

[20]  L. Claesson‐Welsh,et al.  VEGF receptor signalling ? in control of vascular function , 2006, Nature Reviews Molecular Cell Biology.

[21]  G. Tucker Integrins: Molecular targets in cancer therapy , 2006, Current oncology reports.

[22]  Gáspár Jékely,et al.  Regulators of endocytosis maintain localized receptor tyrosine kinase signaling in guided migration. , 2005, Developmental cell.

[23]  E. Calabrese Cancer Biology and Hormesis: Human Tumor Cell Lines Commonly Display Hormetic (Biphasic) Dose Responses , 2005, Critical reviews in toxicology.

[24]  D. Hicklin,et al.  Elevated Flk1 (Vascular Endothelial Growth Factor Receptor 2) Signaling Mediates Enhanced Angiogenesis in β3-Integrin–Deficient Mice , 2004, Cancer Research.

[25]  R. Moats,et al.  In vivo Near-Infrared Fluorescence Imaging of Integrin αvβ3 in Brain Tumor Xenografts , 2004, Cancer Research.

[26]  B. Teicher,et al.  Gene Expression Analysis of Tumor Spheroids Reveals a Role for Suppressed DNA Mismatch Repair in Multicellular Resistance to Alkylating Agents , 2004, Molecular and Cellular Biology.

[27]  C. Rüegg,et al.  Manganese-induced integrin affinity maturation promotes recruitment of αVβ3 integrin to focal adhesions in endothelial cells: evidence for a role of phosphatidylinositol 3-kinase and Src , 2004, Thrombosis and Haemostasis.

[28]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[29]  Kenneth J. Hillan,et al.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.

[30]  A. Richmond,et al.  Rab11-family interacting protein 2 and myosin Vb are required for CXCR2 recycling and receptor-mediated chemotaxis. , 2004, Molecular biology of the cell.

[31]  G. Gillespie,et al.  Human Malignant Glioma Therapy Using Anti-αVβ3 Integrin Agents , 2004, Journal of Neuro-Oncology.

[32]  Michael S. Pepper,et al.  αvβ3 and αvβ5 integrin antagonists inhibit angiogenesis in vitro , 2004, Angiogenesis.

[33]  A. Reynolds,et al.  Integrins in angiogenesis: multitalented molecules in a balancing act , 2003, Cell and Tissue Research.

[34]  G. Tucker Alpha v integrin inhibitors and cancer therapy. , 2003, Current opinion in investigational drugs.

[35]  J. Verweij,et al.  Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours , 2003 .

[36]  J. Gratton,et al.  Vascular Endothelial Growth Factor-dependent Down-regulation of Flk-1/KDR Involves Cbl-mediated Ubiquitination CONSEQUENCES ON NITRIC OXIDE PRODUCTION FROM ENDOTHELIAL CELLS* , 2003 .

[37]  S. Goodman,et al.  alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro. , 2003, Angiogenesis.

[38]  Arnoud Sonnenberg,et al.  The fibronectin-binding integrins α5β1 and αvβ3 differentially modulate RhoA–GTP loading, organization of cell matrix adhesions, and fibronectin fibrillogenesis , 2002, The Journal of cell biology.

[39]  G. Tucker,et al.  Substituted benzocyloheptenes as potent and selective αv integrin antagonists , 2002 .

[40]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[41]  R. Hynes A reevaluation of integrins as regulators of angiogenesis , 2002, Nature Medicine.

[42]  K. Weinberg,et al.  αv‐Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin , 2002, International journal of cancer.

[43]  K. Messmer,et al.  Inhibition of the alpha-ν integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo , 2002, British Journal of Cancer.

[44]  D. Taverna,et al.  Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrins , 2002, Nature Medicine.

[45]  M. Roberts,et al.  PDGF-regulated rab4-dependent recycling of αvβ3 integrin from early endosomes is necessary for cell adhesion and spreading , 2001, Current Biology.

[46]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[47]  F. Ross,et al.  Superactivation of integrin (α)v(β)3 by low antagonist concentrations , 2001 .

[48]  F. Ross,et al.  Superactivation of integrin alphavbeta3 by low antagonist concentrations. , 2001, Journal of cell science.

[49]  Sibylle Ziegler,et al.  Noninvasive Imaging of αvβ3 Integrin Expression Using 18F-labeled RGD-containing Glycopeptide and Positron Emission Tomography , 2001 .

[50]  Hiroyuki Shimada,et al.  Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an &agr;v Integrin Antagonist , 2001, Neurosurgery.

[51]  M. Roberts,et al.  PDGF-regulated rab4-dependent recycling of alphavbeta3 integrin from early endosomes is necessary for cell adhesion and spreading. , 2001, Current biology : CB.

[52]  J. Segall,et al.  Epidermal growth factor receptor distribution during chemotactic responses. , 2000, Molecular biology of the cell.

[53]  F. Mitjans,et al.  In vivo therapy of malignant melanoma by means of antagonists of αv integrins , 2000 .

[54]  D. Hicklin,et al.  Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. , 1999, Cancer research.

[55]  Horst Kessler,et al.  N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists , 1999 .

[56]  G. Neufeld,et al.  Vascular endothelial growth factor (VEGF) and its receptors , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[57]  M. Bretscher Moving Membrane up to the Front of Migrating Cells , 1996, Cell.

[58]  F. Sarkar,et al.  Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. , 1995, The Journal of clinical investigation.

[59]  D. Cheresh,et al.  Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.

[60]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[61]  D. Gale Molecular targets in cancer therapy. , 2003, Seminars in oncology nursing.

[62]  D. Gale MOLECULAR TARGETS FOR CANCER THERAPY , 1990, The Lancet.